US20230273107A1 - Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid - Google Patents
Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid Download PDFInfo
- Publication number
- US20230273107A1 US20230273107A1 US18/144,954 US202318144954A US2023273107A1 US 20230273107 A1 US20230273107 A1 US 20230273107A1 US 202318144954 A US202318144954 A US 202318144954A US 2023273107 A1 US2023273107 A1 US 2023273107A1
- Authority
- US
- United States
- Prior art keywords
- colloid
- molecules
- continuous phase
- concentration
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000084 colloidal system Substances 0.000 title claims abstract description 144
- 238000000034 method Methods 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000008569 process Effects 0.000 title claims abstract description 19
- 239000002245 particle Substances 0.000 claims abstract description 75
- 239000000523 sample Substances 0.000 abstract description 38
- 238000012360 testing method Methods 0.000 abstract description 31
- 239000013068 control sample Substances 0.000 abstract description 16
- 239000012141 concentrate Substances 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 description 28
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 24
- 239000002105 nanoparticle Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 16
- 229960000907 methylthioninium chloride Drugs 0.000 description 16
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 15
- 229910052737 gold Inorganic materials 0.000 description 15
- 239000010931 gold Substances 0.000 description 15
- 229960003405 ciprofloxacin Drugs 0.000 description 12
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 12
- 229940012189 methyl orange Drugs 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- 239000012901 Milli-Q water Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002923 metal particle Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000004062 sedimentation Methods 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000013528 metallic particle Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 238000013103 analytical ultracentrifugation Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000000412 dendrimer Substances 0.000 description 3
- 229920000736 dendritic polymer Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 101150054032 lspA gene Proteins 0.000 description 3
- 239000002077 nanosphere Substances 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002073 nanorod Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- GWOLZNVIRIHJHB-UHFFFAOYSA-N 11-mercaptoundecanoic acid Chemical compound OC(=O)CCCCCCCCCCS GWOLZNVIRIHJHB-UHFFFAOYSA-N 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- -1 citrate ions Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 239000002509 fulvic acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/01—Arrangements or apparatus for facilitating the optical investigation
- G01N21/03—Cuvette constructions
- G01N21/07—Centrifugal type cuvettes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N2015/0038—Investigating nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
- G01N2015/045—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates by optical analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/04—Investigating sedimentation of particle suspensions
- G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
- G01N2015/045—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates by optical analysis
- G01N2015/047—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates by optical analysis by static multidetectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N2035/00465—Separating and mixing arrangements
- G01N2035/00495—Centrifuges
Definitions
- the present invention relates to the field of nanotechnology, more specifically to the evaluation of the interaction between particles of a colloid and molecules dissolved in the same colloid, even more specifically to a process, a composition, a kit, and a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid.
- Colloids are systems in which particles, having at least one dimension between 1 and 1,000 [nm], are dispersed in a continuous phase of a composition other than particle composition (IUPAC).
- Colloids have various industrial applications, for example, currently in the development of new pharmacological forms the use of colloids for the development of biomedical applications is promoted. Colloids are considered as a stable alternative of dispersion of molecules that can be applied in a specific tissue, which provide a sustained release of a molecule of interest, for example, a cytotoxic drug in a tumor, an analgesic or other. In order to advance in this delicate field of application, it is necessary to know the interaction between the particles of the colloid, and molecules dissolved in the same colloid.
- the particles of a colloid may be metal particles, such as gold, silver, copper, iron, nickel or cobalt particles, which may or may not have an ionic charge. Additionally, these particles may be functionalized, for example, with mercaptoalkanoic acid molecules.
- the particles of a colloid may also be non-metallic particles, as in the case of dendrimers, liposomes, protein dispersions, and nucleic acid dispersions.
- the molecules dissolved in a colloid establish reversible interactions with the components of the colloid, that is, the continuous phase and the dispersed particles of the colloid. With reversible interactions, equilibrium constants can be measured, thus evaluating the interaction between dispersed particles and molecules dissolved in the same colloid.
- PM n represents the complex formed between the particles of a colloid and molecules that interact with the particles of the colloid
- M dis represents the molecules dissolved in the continuous phase of the colloid
- LSPs resonance spectrometry allowed to develop a method that optimizes the detection of interaction between metallic nanorods and peptide molecules (PharmaDiagnostics NV, Patent Application US20150024402, Jan. 22, 2015).
- the interaction was studied following changes in the wavelength of the maximum absorbance of the LSP resonance band of the nanorods after exposure of the particles to the peptides.
- the invention provides a process for obtaining a monophasic liquid composition equivalent to the continuous phase of a colloid.
- the composition must be extracted from a colloid and is used to obtain control samples during the execution of a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid.
- the invention also provides a monophasic liquid composition extracted from a colloid.
- the invention also provides the components of a Kit.
- the Kit contains a volume of a colloid and a volume of a monophasic liquid composition extracted from a fraction of the same colloid, and which is equivalent to the continuous phase of the colloid.
- the Kit allows the user to measure the concentration of molecules of interest dissolved in the continuous phase of the colloid provided in the Kit.
- the concentration values of dissolved molecules obtained with the Kit components are used as reference values.
- the reference values allow the user to study in an accurate way the interaction between the molecules of interest (for example, drug molecules), and particles of other colloids also of interest.
- the invention provides a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid.
- the method comprises the obtention of a test sample and a control sample.
- the test sample contains molecules dissolved in a colloid
- the control sample contains molecules dissolved in a particle-free solution extracted from a fraction of the same colloid.
- a particle-free volume is obtained from the test sample. The concentration value of dissolved molecules in this volume is measured by comparison with the control sample.
- Kit components Instructions are also provided so that the user can manipulate the Kit components. These instructions contain the information included in the method of the present invention.
- FIG. 1 Process scheme for obtaining volumes of a colloid with continuous phase containing low concentration of residual compounds.
- FIG. 2 Scheme of method for measuring the concentration of molecules dissolved in the continuous phase of a colloid.
- FIG. 3 Process scheme for obtaining a volume of particle-free solution extracted from a colloid.
- FIG. 4 Visible spectrum of standard AuNP@MUA colloid and standard particle-free solution extracted from a volume of the standard AuNP@MUA colloid.
- FIG. 5 Concentration of methylene blue, methyl orange and ciprofloxacin measured in the control samples and the continuous phase of the AuNP@MUA colloid.
- the present invention relates to a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid, in addition to a process for obtaining a volume of particle-free solution from a volume of a colloid, a particle-free monophasic composition obtained from a volume of a colloid, and a kit for measuring the concentration of molecules of interest dissolved in the continuous phase of a colloid.
- the present invention uses volumes of colloid with continuous phase that contain low concentration of residual compounds. This is because, during the synthesis and functionalization of the particles of a colloid, ions and residual molecules dissolved in the continuous phase of the colloid accumulate. These residual molecules interfere during interaction assays between the particles and the molecules of interest.
- the continuous phase of colloids of nanometric gold particles obtained by the trisodium citrate reduction method contains a high concentration of organic molecules derived from the incomplete oxidation of citrate ions and gold that was not incorporated into the structure of the nanometric particles.
- molecules not adsorbed to the surface of the particles also accumulate in the continuous phase of the colloid.
- the process outlined in FIG. 1 is used to decrease the concentration of residual compounds in the continuous phase of colloids containing a high concentration of residual compounds.
- the process includes repetitive cycles of, a) concentrating the particles, b) discarding particle-free continuous phase and storing concentrated particles, and c) adding buffer volumes to the stored particles.
- the buffer must keep the particles dispersed, avoiding flocculation or aggregation phenomena.
- the volumes of colloid thus obtained can be standardized taking as a reference a parameter proportional to the concentration of the dispersed particles. Fractions of colloid with continuous phase containing low concentration of residual compounds are used in concentration measurement assays of molecules dissolved in the continuous phase of the same colloid, or in other interaction assays.
- “Molecule” represents a defined chemical species.
- Particles is considered equivalent to “dispersed particles”, “particles of a colloid” and “particles contained in a colloid”.
- Nanoparticle is considered equivalent to particles with a diameter smaller than 150 [nm], equivalent to “dispersed nanoparticles”, “nanoparticles of a colloid” and “nanoparticles contained in a colloid”.
- Test sample represents a volume of colloid that contains a defined number of dissolved molecules.
- Control sample represents a volume of a solution extracted from a colloid also used to obtain a test sample, which does not contain detectable particles, and which contains a defined number of dissolved molecules.
- OD means Optical Density and represents a parameter proportional to the concentration of nanoparticles in the colloid.
- g means intensity of the Earth's gravitational field, whose value on the earth's surface is approximately 9.8 [m/s 2 ].
- Particle-free solution is understood as a monophasic liquid composition extracted from a colloid, and which is equivalent to the continuous phase of the same colloid.
- the invention provides a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid ( FIG. 2 ).
- the concentration of molecules dissolved in a fraction of the particle free colloid is measured.
- the method obtains a test sample and a control sample.
- the test sample contains molecules dissolved in a colloid
- the control sample contains the same concentration of molecules dissolved in a particle-free solution extracted from the same colloid used to obtain the test sample.
- the control sample is equivalent to a concentration of molecules dissolved in the continuous phase of the colloid, but does not include the effect of the interaction between molecules and particles.
- the samples are exposed to a condition that allows the particles of the test sample to be concentrated.
- [FC] corresponds to the concentration of molecules dissolved in the continuous phase of a colloid
- Ho corresponds to the value of the concentration of molecules used during the sampling steps
- @ mp corresponds to the empirical value of a parameter proportional to the number of molecules contained in a volume of particle-free test sample
- @ mc corresponds to the empirical value of the same parameter proportional to the number of molecules contained in a volume of control sample.
- the concentration value obtained from this equation is equivalent to the concentration of molecules dissolved in the continuous phase of the colloid.
- the method for measuring the concentration of molecules dissolved in the continuous phase of a colloid comprises the steps of:
- the colloid comprises dispersions of particles chosen from: metal particles, metal oxides, silicates, dendrimers, liposomes, proteins, nucleic acids, polysaccharides, fulvic acids, humic acids, or synthetic polymers; specifically, the colloid comprises particles of gold, silver or copper, iron, nickel and cobalt, functionalized or not. More specifically, the colloid comprises nanometric particles of gold, silver or copper, iron, nickel and cobalt, functionalized with molecules containing a sulfhydryl functional group, or with molecules that have an amine functional group, or molecules with other functional groups that can react covalently with the surface of the particles.
- the dissolved molecules have a molecular mass between 50 [g/mol] and 200,000 [g/mol].
- step c) can be performed by centrifugation, ultrafiltration, or magnetization, depending on the physical and chemical characteristics of the dispersed particles and the continuous phase of the colloid.
- the particles when using metal particles, if centrifugation is used, it is performed at between 20,000 and 30,000 ⁇ g for a time between 5 to 30 [min].
- the particles are concentrated in the retentate after exposure of the filter to an acceleration of 1,000 to 10,000 ⁇ g, or exposure of the bottom of the filter to a pressure lower than atmospheric pressure.
- these parameters may vary depending on the sedimentation coefficient of the particles and the viscosity of the continuous phase.
- the particles possess magnetic properties they are concentrated by exposure to a magnet.
- step g) any available technique can be used to measure the number or concentration of dissolved molecules, such as: reversed-phase high-performance liquid chromatography and visible UV detection; reversed-phase high-performance liquid chromatography and infrared detection; liquid chromatography coupled to mass spectrometry; gas chromatography coupled to mass spectrometry; visible UV spectrophotometry and spectrofluorimetry.
- any available technique can be used to measure the number or concentration of dissolved molecules, such as: reversed-phase high-performance liquid chromatography and visible UV detection; reversed-phase high-performance liquid chromatography and infrared detection; liquid chromatography coupled to mass spectrometry; gas chromatography coupled to mass spectrometry; visible UV spectrophotometry and spectrofluorimetry.
- the invention provides a process for obtaining a monophasic liquid composition from a volume of colloid.
- the composition also provided in the kit, is free of particles and equivalent to the continuous phase of the colloid from which it was extracted.
- the process for obtaining the volume of particle-free solution comprises the steps of a) concentrating the particles of a colloid sample, b) recovering a fraction of the particle-free sample, c) measuring in the recovered sample a parameter proportional to the concentration of particles of the colloid, and d) storing the particle-free continuous phase. Fractions of the volume of particle-free solution thus obtained can be used to obtain control samples. Control samples are used in measurement assays of concentration of molecules dissolved in the continuous phase of a colloid, or in other interaction assays.
- step a) can be performed by centrifugation, ultrafiltration, or magnetization, depending on the physical and chemical characteristics of the dispersed particles and the continuous phase of the colloid.
- the particles when using metal particles, if centrifugation is used, it is performed at between 20,000 to 30,000 ⁇ g for a time between 5 to 30 [min].
- the particles are concentrated in the retentate after exposure of the filter to an acceleration of 1,000 to 10,000 ⁇ g, or exposure of the bottom of the filter to a pressure lower than atmospheric pressure.
- these parameters may vary depending on the sedimentation coefficient of the particles and the viscosity of the continuous phase.
- the particles possess magnetic properties they are concentrated by exposure to a magnet.
- the invention provides a Kit that allows to measure the concentration of molecules of interest dissolved in the continuous phase of a colloid provided in the Kit.
- the Kit contains a volume of colloid and a volume of particle-free solution extracted from a fraction of the same colloid.
- the composition is obtained following the instructions of the process described previously.
- Kit components can be obtained from colloids of gold nanometric particles functionalized with mercaptoalkanoic acid molecules. These colloids are stable and have been widely characterized in scientific literature. The stability of the colloid allows the storage and transport of the product for prolonged periods of time.
- Kit components following the instructions of the method set forth in the present invention, allows the laboratory user to obtain empirical concentration values of molecules of interest dissolved in the continuous phase of the colloid provided in the Kit.
- concentration values of dissolved molecules obtained with the components of the Kit can be used as reference values.
- the reference values allow the user to accurately measure the concentration of molecules of interest dissolved in the continuous phase of other colloids of interest.
- Example 1 and Example 2 describe the composition of one of the possible forms that the components of the Kit in question can acquire
- Example 3 describes possible uses of the components of the Kit for measuring the concentration of different molecules dissolved in the continuous phase of the colloid obtained as described in example 1.
- Example 1 Obtaining a Standard Colloid of Gold Nanoparticles Functionalized with 11-Mercaptoundecanoic Acid and with a Continuous Phase Containing Low Concentration of Residual Compounds (Standard AuNP@MUA Colloid)
- AuNP@MUA colloid gold nanoparticles with hydrodynamic diameter of 10 [nm] (50 [ml]) synthesized by citrate ion reduction were functionalized by exposure to a concentration of 11-mercaptoundenoic acid (MUA) of 100 [ ⁇ M].
- MUA 11-mercaptoundenoic acid
- the volume of functionalized nanoparticles was subjected to ultrafiltration by centrifugation using a commercial filter with exclusion size equal to 100 [kDa]. The sample was centrifuged at 4,000 ⁇ g for 15 min and a 1 [ml] retentate enriched in nanoparticles was obtained.
- the functionalization of the nanoparticles with MUA molecules generates a hydrophobic layer of methylene groups located just above the surface of the metal core, and an outer layer containing negative electrical charges, because the carboxylic group of part of the 11-Mercaptoundenoic acid molecules remains deprotonated (zeta potential of the colloid equal to ⁇ 33.5 [mV]).
- This colloid is used to obtain test samples during concentration measurement assays of molecules dissolved in the continuous phase of the standard AuNP@MUA colloid, and in other interaction assays.
- Example 2 Obtaining a Standard Particle-Free Solution with a Composition Equivalent to the Continuous Phase of the Standard AuNP@MUA Colloid
- the standard AuNP@MUA colloid nanoparticles were concentrated by sedimentation. To this end, a volume of 1.5 [ml] of AuNP@MUA colloid was centrifuged at 24,000 ⁇ g for 15 [min]. A volume of 1.4 [ml] of continuous phase free of AuNP@MUA nanoparticles was recovered and stored. As can be seen in FIG. 4 , the volume of particle-free solution did not show an absorption band associated with the LSP of the gold nanoparticles, indicating that the particle-free solution obtained from the AuNP@MUA colloid does not contain detectable nanoparticles.
- This particle-free solution is used to obtain control samples during concentration measurement assays of molecules dissolved in the continuous phase of the standard AuNP@MUA colloid, and in other interaction assays. If necessary, it can also be used to dilute volumes of the standard AuNP@MUA colloid.
- the amount of methyl orange was measured in all recovered volumes by RP-HPLC and visible UV detection using a diode array detector.
- the methyl orange signal was detected at a wavelength of 432 [nm] (mAU).
- the amount of methyl orange was measured as a value of the signal integration area corresponding to the elution peak (mAU ⁇ min).
- Ciprofloxacin Ciprofloxacin
- the amount of ciprofloxacin was measured by RP-HPLC and visible UV detection using a diode array detector.
- the ciprofloxacin signal was detected at a wavelength of 278 [nm] (mAU).
- the amount of ciprofloxacin was measured as value of the signal integration area corresponding to the elution peak (mAU ⁇ min).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
A method for measuring a concentration of molecules, characterized in that the method measures the concentration of molecules dissolved in a continuous phase of a colloid and includes obtaining a test sample by mixing a number of molecules with a volume of colloid, obtaining a control sample by mixing a number of molecules with a volume of a composition comprising a particle-free solution extracted from a fraction of the continuous phase of same colloid used in the obtaining the test sample, so that a value of the concentration of molecules in the mixture is equal to the value of the concentration of molecules in the test sample obtained in the obtaining the test sample, and submitting the test and the control samples obtained in the obtaining the test sample and obtaining the control sample to a process in order to concentrate the particles of the test sample.
Description
- The present application is a divisional of U.S. patent application Ser. No. 16/622,256, filed on Dec. 12, 2019, which in turn is a national phase entry of international patent application No. PCT/CL2018/050058 filed on Jul. 27, 2018, which claims the benefit of CL patent application No. 1945-2017 filed on Jul. 30, 2017, the disclosure of which are expressly incorporated herein by reference.
- The present invention relates to the field of nanotechnology, more specifically to the evaluation of the interaction between particles of a colloid and molecules dissolved in the same colloid, even more specifically to a process, a composition, a kit, and a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid.
- Colloids are systems in which particles, having at least one dimension between 1 and 1,000 [nm], are dispersed in a continuous phase of a composition other than particle composition (IUPAC).
- Colloids have various industrial applications, for example, currently in the development of new pharmacological forms the use of colloids for the development of biomedical applications is promoted. Colloids are considered as a stable alternative of dispersion of molecules that can be applied in a specific tissue, which provide a sustained release of a molecule of interest, for example, a cytotoxic drug in a tumor, an analgesic or other. In order to advance in this delicate field of application, it is necessary to know the interaction between the particles of the colloid, and molecules dissolved in the same colloid.
- The particles of a colloid may be metal particles, such as gold, silver, copper, iron, nickel or cobalt particles, which may or may not have an ionic charge. Additionally, these particles may be functionalized, for example, with mercaptoalkanoic acid molecules. The particles of a colloid may also be non-metallic particles, as in the case of dendrimers, liposomes, protein dispersions, and nucleic acid dispersions.
- The molecules dissolved in a colloid establish reversible interactions with the components of the colloid, that is, the continuous phase and the dispersed particles of the colloid. With reversible interactions, equilibrium constants can be measured, thus evaluating the interaction between dispersed particles and molecules dissolved in the same colloid.
- During the reversible interaction of molecules with particles of a colloid, two populations of molecules are generated. A population of molecules that interacts with the particles of the colloid, while another population of the molecules remains dissolved in the continuous phase of the colloid. This reversible interaction can be mediated by different phenomena, such as liophobia of dissolved molecules, Coulombic forces of attraction or repulsion between particles and dissolved molecules, among others.
- The reversible interaction between dispersed particles and molecules dissolved in the colloid can be described by the reaction:
- where PMn represents the complex formed between the particles of a colloid and molecules that interact with the particles of the colloid, and where Mdis represents the molecules dissolved in the continuous phase of the colloid.
- In the state of the art, there are methods based on analytical ultracentrifugation techniques and localized surface plasmon (LSP) resonance spectrometry that allow to evaluate the interaction between particles of a colloid and molecules dissolved in the same colloid. For example, the study of the sedimentation pattern of gold nanospheres in the presence of albumin molecules by analytical ultracentrifugation coupled to LSPs resonance detection allowed to infer the number of protein molecules adsorbed onto metal nanospheres (Bekdemir and Stellacci, Nat Commun 7, 13121:28, 2016). Complex mathematical approaches indicated that, at equilibrium, a gold nanosphere can interact with 2 to 27 albumin molecules, depending on the size and chemical environment of the nanoparticle. In another example, the use of LSPs resonance spectrometry allowed to develop a method that optimizes the detection of interaction between metallic nanorods and peptide molecules (PharmaDiagnostics NV, Patent Application US20150024402, Jan. 22, 2015). In this case, the interaction was studied following changes in the wavelength of the maximum absorbance of the LSP resonance band of the nanorods after exposure of the particles to the peptides.
- Although both methods can describe the interaction between peptide molecules and colloidal particles, they are based on techniques that limit interaction studies to restricted experimental conditions. For example, the use of analytical ultracentrifugation allows to determine changes in the sedimentation coefficient of particles, thus excluding from its analysis the study of interactions between particles of a colloid and molecules of low molecular mass. On the other hand, patent application US20150024402, which evaluates interactions by LSPs resonance spectrometry, limits its applications to the study of metal particles, excluding from its analysis the study of particulate systems without LSP, such as dendrimers, lipid particles, protein dispersions, emulsions, nucleic acid dispersions, synthetic polymer dispersions, etc.
- According to scientific literature (Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., Corrie, S. R.: ‘Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date, Pharm. Res., 2016, 33, (10), pp. 2373-2387; 2*Ragelle, H., Danhier, F., Préat, V., Langer, R., Anderson, D. G.: ‘Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures, Expert Opin. Drug Deliv., 2017, 14, (7), pp. 851-864), it is still necessary to have products and methods for measuring the concentration of different molecules dissolved in the continuous phase of colloids in order to understand the interaction established, for example, between drug molecules and colloidal particles, whose composition includes both metallic and non-metallic particles. The present invention provides a solution to these limitations of previous technologies.
- The invention provides a process for obtaining a monophasic liquid composition equivalent to the continuous phase of a colloid. The composition must be extracted from a colloid and is used to obtain control samples during the execution of a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid.
- The invention also provides a monophasic liquid composition extracted from a colloid.
- In addition, the invention also provides the components of a Kit. The Kit contains a volume of a colloid and a volume of a monophasic liquid composition extracted from a fraction of the same colloid, and which is equivalent to the continuous phase of the colloid. The Kit allows the user to measure the concentration of molecules of interest dissolved in the continuous phase of the colloid provided in the Kit. The concentration values of dissolved molecules obtained with the Kit components are used as reference values. The reference values allow the user to study in an accurate way the interaction between the molecules of interest (for example, drug molecules), and particles of other colloids also of interest.
- Finally, the invention provides a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid. To this end, the method comprises the obtention of a test sample and a control sample. The test sample contains molecules dissolved in a colloid, and the control sample contains molecules dissolved in a particle-free solution extracted from a fraction of the same colloid. To measure the concentration of molecules dissolved in the continuous phase of the colloid, a particle-free volume is obtained from the test sample. The concentration value of dissolved molecules in this volume is measured by comparison with the control sample.
- Instructions are also provided so that the user can manipulate the Kit components. These instructions contain the information included in the method of the present invention.
-
FIG. 1 . Process scheme for obtaining volumes of a colloid with continuous phase containing low concentration of residual compounds. -
FIG. 2 . Scheme of method for measuring the concentration of molecules dissolved in the continuous phase of a colloid. -
FIG. 3 . Process scheme for obtaining a volume of particle-free solution extracted from a colloid. -
FIG. 4 . Visible spectrum of standard AuNP@MUA colloid and standard particle-free solution extracted from a volume of the standard AuNP@MUA colloid. -
FIG. 5 . Concentration of methylene blue, methyl orange and ciprofloxacin measured in the control samples and the continuous phase of the AuNP@MUA colloid. - The present invention relates to a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid, in addition to a process for obtaining a volume of particle-free solution from a volume of a colloid, a particle-free monophasic composition obtained from a volume of a colloid, and a kit for measuring the concentration of molecules of interest dissolved in the continuous phase of a colloid.
- The present invention uses volumes of colloid with continuous phase that contain low concentration of residual compounds. This is because, during the synthesis and functionalization of the particles of a colloid, ions and residual molecules dissolved in the continuous phase of the colloid accumulate. These residual molecules interfere during interaction assays between the particles and the molecules of interest.
- For example, the continuous phase of colloids of nanometric gold particles obtained by the trisodium citrate reduction method contains a high concentration of organic molecules derived from the incomplete oxidation of citrate ions and gold that was not incorporated into the structure of the nanometric particles. In addition, after functionalization of the nanometric particles with thiolated compounds, molecules not adsorbed to the surface of the particles also accumulate in the continuous phase of the colloid.
- Then, the process outlined in
FIG. 1 is used to decrease the concentration of residual compounds in the continuous phase of colloids containing a high concentration of residual compounds. The process includes repetitive cycles of, a) concentrating the particles, b) discarding particle-free continuous phase and storing concentrated particles, and c) adding buffer volumes to the stored particles. As a condition, the buffer must keep the particles dispersed, avoiding flocculation or aggregation phenomena. The volumes of colloid thus obtained can be standardized taking as a reference a parameter proportional to the concentration of the dispersed particles. Fractions of colloid with continuous phase containing low concentration of residual compounds are used in concentration measurement assays of molecules dissolved in the continuous phase of the same colloid, or in other interaction assays. - As used in the present invention, the following terms should be understood as follows:
- “Molecule” represents a defined chemical species.
- “Particles” is considered equivalent to “dispersed particles”, “particles of a colloid” and “particles contained in a colloid”.
- “Nanoparticle” is considered equivalent to particles with a diameter smaller than 150 [nm], equivalent to “dispersed nanoparticles”, “nanoparticles of a colloid” and “nanoparticles contained in a colloid”.
- “Test sample” represents a volume of colloid that contains a defined number of dissolved molecules.
- “Control sample” represents a volume of a solution extracted from a colloid also used to obtain a test sample, which does not contain detectable particles, and which contains a defined number of dissolved molecules.
- “OD” means Optical Density and represents a parameter proportional to the concentration of nanoparticles in the colloid.
- “g” means intensity of the Earth's gravitational field, whose value on the earth's surface is approximately 9.8 [m/s2].
- “Particle-free solution” is understood as a monophasic liquid composition extracted from a colloid, and which is equivalent to the continuous phase of the same colloid.
- All other terms used in the present invention should be interpreted in a manner similar to that set forth in the scientific literature. Furthermore, it is indicated that in the present invention the steps of the method and the process can operate in sequences other than those mentioned or illustrated in this description.
- The invention provides a method for measuring the concentration of molecules dissolved in the continuous phase of a colloid (
FIG. 2 ). In general terms, the concentration of molecules dissolved in a fraction of the particle free colloid is measured. To evaluate this, in a first part the method obtains a test sample and a control sample. The test sample contains molecules dissolved in a colloid, and the control sample contains the same concentration of molecules dissolved in a particle-free solution extracted from the same colloid used to obtain the test sample. Under this design, the control sample is equivalent to a concentration of molecules dissolved in the continuous phase of the colloid, but does not include the effect of the interaction between molecules and particles. Subsequently, the samples are exposed to a condition that allows the particles of the test sample to be concentrated. After this process, if there is attractive interaction between the molecules and the particles, a portion of the test sample will be enriched in particles and molecules, while another majority portion will be free of particles and will contain a lower concentration of molecules. Then, a particle-free volume is recovered from the test sample. The fraction recovered is equivalent to the continuous phase of the colloid and includes the effect of the interaction between molecules and particles. Finally, the concentration of molecules dissolved in the continuous phase of the colloid is measured using equation 1: -
- where [FC] corresponds to the concentration of molecules dissolved in the continuous phase of a colloid, Ho corresponds to the value of the concentration of molecules used during the sampling steps, @mp corresponds to the empirical value of a parameter proportional to the number of molecules contained in a volume of particle-free test sample, and @mc corresponds to the empirical value of the same parameter proportional to the number of molecules contained in a volume of control sample. The concentration value obtained from this equation is equivalent to the concentration of molecules dissolved in the continuous phase of the colloid.
- According to the above, the method for measuring the concentration of molecules dissolved in the continuous phase of a colloid comprises the steps of:
-
- a) Obtaining a test sample by mixing a number of molecules with a volume of colloid;
- b) Obtaining a control sample by mixing a number of molecules with a volume of particle-free solution extracted from a fraction of the same colloid used in step a), so that the value of the concentration of molecules in the mixture is equal to the value of the concentration of molecules in the test sample obtained in step a);
- c) Submitting the samples obtained in steps a) and b) to a process in order to concentrate the particles of the test sample obtained in step a);
- d) Recovering a particle-free volume from the test sample obtained in step c);
- e) Recovering a volume from the control sample obtained in step c);
- f) Measuring in the volume of the test sample recovered in step d) the value of a parameter proportional to the number of molecules contained in the sample volume;
- g) Measuring in the volume of control sample recovered in step e) the value of the same parameter proportional to the number of molecules contained in the sample volume;
- h) Measuring the concentration of molecules in the continuous phase of the colloid using the equation:
-
-
- where [FC] corresponds to the concentration of molecules dissolved in the continuous phase of a colloid, Ho corresponds to the value of the concentration of molecules used during the sampling steps, @mp corresponds to the empirical value of a parameter proportional to the number of molecules contained in a volume of particle-free test sample obtained in step f), and @mc corresponds to the empirical value of the same parameter, but measured in the control sample obtained in step g).
- The colloid comprises dispersions of particles chosen from: metal particles, metal oxides, silicates, dendrimers, liposomes, proteins, nucleic acids, polysaccharides, fulvic acids, humic acids, or synthetic polymers; specifically, the colloid comprises particles of gold, silver or copper, iron, nickel and cobalt, functionalized or not. More specifically, the colloid comprises nanometric particles of gold, silver or copper, iron, nickel and cobalt, functionalized with molecules containing a sulfhydryl functional group, or with molecules that have an amine functional group, or molecules with other functional groups that can react covalently with the surface of the particles.
- On the other hand, in the method of the invention the dissolved molecules have a molecular mass between 50 [g/mol] and 200,000 [g/mol].
- The steps of the method of the invention can be performed by any method available in the art, for example, step c) can be performed by centrifugation, ultrafiltration, or magnetization, depending on the physical and chemical characteristics of the dispersed particles and the continuous phase of the colloid.
- Preferably, when using metal particles, if centrifugation is used, it is performed at between 20,000 and 30,000×g for a time between 5 to 30 [min]. For metallic and non-metallic particles, if ultrafiltration is used, the particles are concentrated in the retentate after exposure of the filter to an acceleration of 1,000 to 10,000×g, or exposure of the bottom of the filter to a pressure lower than atmospheric pressure. However, these parameters may vary depending on the sedimentation coefficient of the particles and the viscosity of the continuous phase. When the particles possess magnetic properties, they are concentrated by exposure to a magnet.
- Finally, in step g) any available technique can be used to measure the number or concentration of dissolved molecules, such as: reversed-phase high-performance liquid chromatography and visible UV detection; reversed-phase high-performance liquid chromatography and infrared detection; liquid chromatography coupled to mass spectrometry; gas chromatography coupled to mass spectrometry; visible UV spectrophotometry and spectrofluorimetry.
- In addition, the invention provides a process for obtaining a monophasic liquid composition from a volume of colloid. The composition, also provided in the kit, is free of particles and equivalent to the continuous phase of the colloid from which it was extracted. As shown in
FIG. 3 , the process for obtaining the volume of particle-free solution comprises the steps of a) concentrating the particles of a colloid sample, b) recovering a fraction of the particle-free sample, c) measuring in the recovered sample a parameter proportional to the concentration of particles of the colloid, and d) storing the particle-free continuous phase. Fractions of the volume of particle-free solution thus obtained can be used to obtain control samples. Control samples are used in measurement assays of concentration of molecules dissolved in the continuous phase of a colloid, or in other interaction assays. - The step of concentration of particles included in the process can be performed by any method available in the art, for example, step a) can be performed by centrifugation, ultrafiltration, or magnetization, depending on the physical and chemical characteristics of the dispersed particles and the continuous phase of the colloid.
- Preferably, when using metal particles, if centrifugation is used, it is performed at between 20,000 to 30,000×g for a time between 5 to 30 [min]. For metallic and non-metallic particles, if ultrafiltration is used, the particles are concentrated in the retentate after exposure of the filter to an acceleration of 1,000 to 10,000×g, or exposure of the bottom of the filter to a pressure lower than atmospheric pressure. However, these parameters may vary depending on the sedimentation coefficient of the particles and the viscosity of the continuous phase. When the particles possess magnetic properties, they are concentrated by exposure to a magnet.
- Finally, the invention provides a Kit that allows to measure the concentration of molecules of interest dissolved in the continuous phase of a colloid provided in the Kit. The Kit contains a volume of colloid and a volume of particle-free solution extracted from a fraction of the same colloid. The composition is obtained following the instructions of the process described previously.
- For example, the Kit components can be obtained from colloids of gold nanometric particles functionalized with mercaptoalkanoic acid molecules. These colloids are stable and have been widely characterized in scientific literature. The stability of the colloid allows the storage and transport of the product for prolonged periods of time.
- The use of the Kit components, following the instructions of the method set forth in the present invention, allows the laboratory user to obtain empirical concentration values of molecules of interest dissolved in the continuous phase of the colloid provided in the Kit. The concentration values of dissolved molecules obtained with the components of the Kit can be used as reference values. The reference values allow the user to accurately measure the concentration of molecules of interest dissolved in the continuous phase of other colloids of interest.
- The invention can be better understood in the light of the examples detailed below, which are illustrative and not limiting thereof. In the context of these examples, Example 1 and Example 2 describe the composition of one of the possible forms that the components of the Kit in question can acquire, and Example 3 describes possible uses of the components of the Kit for measuring the concentration of different molecules dissolved in the continuous phase of the colloid obtained as described in example 1.
- To obtain a volume of AuNP@MUA colloid, gold nanoparticles with hydrodynamic diameter of 10 [nm] (50 [ml]) synthesized by citrate ion reduction were functionalized by exposure to a concentration of 11-mercaptoundenoic acid (MUA) of 100 [μM]. In order to decrease the concentration of residual compounds in the continuous phase of the colloid, the volume of functionalized nanoparticles was subjected to ultrafiltration by centrifugation using a commercial filter with exclusion size equal to 100 [kDa]. The sample was centrifuged at 4,000×g for 15 min and a 1 [ml] retentate enriched in nanoparticles was obtained. Permeate was discarded, and 9 [ml] of 1.2 [mM] sodium citrate buffer was added to the retentate. The ultrafiltration and resuspension process was repeated 6 times, obtaining a colloid rich in gold nanoparticles functionalized with MUA and with a continuous phase containing 1.2 [mM] sodium citrate, traces of gold, and a concentration of MUA equal or less to 1 [pM].
- The functionalization of the nanoparticles with MUA molecules generates a hydrophobic layer of methylene groups located just above the surface of the metal core, and an outer layer containing negative electrical charges, because the carboxylic group of part of the 11-Mercaptoundenoic acid molecules remains deprotonated (zeta potential of the colloid equal to −33.5 [mV]).
- The concentration of the AuNP@MUA particles contained in the colloid was standardized with respect to the optical density value of the maximum absorbance of the LSP band of the gold nanoparticles (OD maximum absorbance of the plasmon band=60/cm) (
FIG. 4 ). - This colloid is used to obtain test samples during concentration measurement assays of molecules dissolved in the continuous phase of the standard AuNP@MUA colloid, and in other interaction assays.
- The standard AuNP@MUA colloid nanoparticles were concentrated by sedimentation. To this end, a volume of 1.5 [ml] of AuNP@MUA colloid was centrifuged at 24,000×g for 15 [min]. A volume of 1.4 [ml] of continuous phase free of AuNP@MUA nanoparticles was recovered and stored. As can be seen in
FIG. 4 , the volume of particle-free solution did not show an absorption band associated with the LSP of the gold nanoparticles, indicating that the particle-free solution obtained from the AuNP@MUA colloid does not contain detectable nanoparticles. - The concentration of AuNP@MUA particles contained in the particle-free solution was standardized with respect to the optical density value of the maximum absorbance of the LSP band of the gold nanoparticles (OD maximum absorbance of the plasmon band=0/cm).
- This particle-free solution is used to obtain control samples during concentration measurement assays of molecules dissolved in the continuous phase of the standard AuNP@MUA colloid, and in other interaction assays. If necessary, it can also be used to dilute volumes of the standard AuNP@MUA colloid.
- The interaction between AuNP@MUA particles and methylene blue molecules was evaluated. To this end, the concentration of methylene blue molecules dissolved in the continuous phase of the standard AuNP@MUA colloid was measured.
- To obtain the test sample, 140 [μl] of standard AuNP@MUA colloid obtained according to example 1 (OD maximum absorbance of the plasmon band=30/cm) were mixed with 5 [μl] of Milli-Q water and with 5 [μl] of a standard solution of methylene blue 60.00 [μM] dissolved in Milli-Q water. To obtain the control sample, 140 [μl] of standard solution obtained according to example 2 (OD maximum absorbance of the plasmon band=0/cm) were mixed with 5 [μl] of Milli-Q water and with 5 [μl] of a standard solution of methylene blue 60.00 [μM] dissolved in Milli-Q water. This results in a concentration of 2.00 [μM] of methylene blue in each sample.
- Subsequently, in order to separate the continuous phase of the AuNP@MUA colloid particles, all samples were centrifuged at 24,000×g for 15 [min]. A volume of 130 [μl] free of nanoparticles was recovered from the test sample and control sample. In all volumes recovered, the amount of methylene blue was measured by reversed-phase high-performance liquid chromatography (RP-HPLC) and visible UV detection using a diode array detector. The methylene blue signal was detected at a wavelength of 665 [nm] (mAU). The amount of methylene blue was measured as the value of the signal integration area corresponding to the elution peak (mAU·min). Test samples (n=3) and control samples (n=3) were obtained and processed independently. Each sample was measured independently.
- The results of the concentration measurement indicated that, after incorporating 2.00 [μM] methylene blue into the colloid, the average concentration of methylene blue dissolved in the continuous phase of the AuNP@MUA colloid is 1.17 [μM], while in the control samples, equivalent to the continuous phase of the colloid, the concentration was 2.00 [μM] (
FIG. 5 ). - Secondly, the interaction between AuNP@MUA particles and methyl orange molecules was evaluated. To this end, the concentration of dissolved methyl orange molecules in the continuous phase of the standard AuNP@MUA colloid was measured. For this, assays identical to those performed with methylene blue were performed, but using a standard solution of methyl orange 60.00 [μM] dissolved in Milli-Q water. This results in a concentration of 2.00 [μM] of methyl orange in each sample. The samples were further processed in the same manner as previously described in section 3.1 for methylene blue.
- The amount of methyl orange was measured in all recovered volumes by RP-HPLC and visible UV detection using a diode array detector. The methyl orange signal was detected at a wavelength of 432 [nm] (mAU). The amount of methyl orange was measured as a value of the signal integration area corresponding to the elution peak (mAU·min). Test samples (n=3) and control samples (n=3) were obtained and processed independently. Each sample was measured independently.
- The concentration measurement results indicated that, after incorporating methyl orange 2.00 [μM] into the colloid, the concentration of methyl orange molecules dissolved in the continuous phase of the standard AuNP@MUA colloid is 2.00 [μM]. The concentration of methyl orange in the control samples, equivalent to the continuous phase of the colloid, was also 2.00 [μM] (
FIG. 5 ). - Thirdly, the interaction between AuNP@MUA particles and ciprofloxacin molecules was evaluated. To this end, the concentration of ciprofloxacin molecules dissolved in the continuous phase of the standard AuNP@MUA colloid was measured. For this, assays identical to those performed with methylene blue were performed, but using a standard solution of ciprofloxacin 60.00 [μM] dissolved in 50% methanol. This results in a concentration of 2.00 [μM] of ciprofloxacin in each sample. The samples were further processed in the same manner as previously described in section 3.1 for methylene blue.
- In all recovered volumes, the amount of ciprofloxacin was measured by RP-HPLC and visible UV detection using a diode array detector. The ciprofloxacin signal was detected at a wavelength of 278 [nm] (mAU). The amount of ciprofloxacin was measured as value of the signal integration area corresponding to the elution peak (mAU·min). Test samples (n=3) and control samples (n=3) were obtained and processed independently. Each sample was measured independently.
- The results of concentration measurement indicated that, after incorporating 2.00 ciprofloxacin [μM] into the colloid, the concentration of ciprofloxacin molecules dissolved in the continuous phase of the standard AuNP@MUA colloid is 0.88 [μM]. The concentration of ciprofloxacin in the control samples, equivalent to the continuous phase of the colloid, was 2.00 [μM] (
FIG. 5 ).
Claims (3)
1. A process for obtaining a particle-free solution composition, characterized in that said process comprises the steps of:
a) concentrating particles contained in a colloid sample for obtaining a continuous phase of the colloid;
b) recovering a fraction of the continuous phase of the colloid;
c) measuring in the recovered fraction of step b) a parameter proportional to the concentration of particles of the colloid; and
d) storing a volume of a particle-free solution which is equivalent to the continuous phase of the colloid sample used in step a).
2. A particle-free solution composition, characterized in that said particle-free solution is extracted from a colloid and is equivalent to a fraction of a continuous phase of the same colloid.
3. A Kit for measuring the concentration of molecules dissolved in the continuous phase of a colloid, characterized in that said kit comprises:
a volume of the colloid; and
a volume of a composition comprising a particle-free solution extracted from a fraction of the continuous phase of the same colloid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/144,954 US20230273107A1 (en) | 2017-07-30 | 2023-05-09 | Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL1945-2017 | 2017-07-30 | ||
CL2017001945A CL2017001945A1 (en) | 2017-07-30 | 2017-07-30 | Method, process, composition and kit to measure concentration of dissolved molecules in the continuous phase of a colloid. |
PCT/CL2018/050058 WO2019023814A1 (en) | 2017-07-30 | 2018-07-27 | Method, process, composition and kit for measuring the concentration of molecules dissolved in the continuous phase of a colloid |
US201916622256A | 2019-12-12 | 2019-12-12 | |
US18/144,954 US20230273107A1 (en) | 2017-07-30 | 2023-05-09 | Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CL2018/050058 Division WO2019023814A1 (en) | 2017-07-30 | 2018-07-27 | Method, process, composition and kit for measuring the concentration of molecules dissolved in the continuous phase of a colloid |
US16/622,256 Division US11680885B2 (en) | 2017-07-30 | 2018-07-27 | Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230273107A1 true US20230273107A1 (en) | 2023-08-31 |
Family
ID=65232120
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/622,256 Active 2039-10-28 US11680885B2 (en) | 2017-07-30 | 2018-07-27 | Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid |
US18/144,954 Pending US20230273107A1 (en) | 2017-07-30 | 2023-05-09 | Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/622,256 Active 2039-10-28 US11680885B2 (en) | 2017-07-30 | 2018-07-27 | Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid |
Country Status (3)
Country | Link |
---|---|
US (2) | US11680885B2 (en) |
CL (1) | CL2017001945A1 (en) |
WO (1) | WO2019023814A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2018001473A1 (en) * | 2018-06-01 | 2019-10-25 | Univ Tecnica Federico Santa Maria Utfsm | Kit and methods to evaluate the adsorbent properties of the surface of a material |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7109247B2 (en) * | 2003-05-30 | 2006-09-19 | 3M Innovative Properties Company | Stabilized particle dispersions containing nanoparticles |
US20070042507A1 (en) | 2003-07-16 | 2007-02-22 | Tsang Shik C | Composite nanoparticles |
GB201202631D0 (en) | 2012-02-16 | 2012-04-04 | Pharmadiagnostics Nv | Method of measuring interaction between molecules |
CL2018001473A1 (en) * | 2018-06-01 | 2019-10-25 | Univ Tecnica Federico Santa Maria Utfsm | Kit and methods to evaluate the adsorbent properties of the surface of a material |
-
2017
- 2017-07-30 CL CL2017001945A patent/CL2017001945A1/en unknown
-
2018
- 2018-07-27 WO PCT/CL2018/050058 patent/WO2019023814A1/en active Application Filing
- 2018-07-27 US US16/622,256 patent/US11680885B2/en active Active
-
2023
- 2023-05-09 US US18/144,954 patent/US20230273107A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2017001945A1 (en) | 2018-10-19 |
US11680885B2 (en) | 2023-06-20 |
WO2019023814A1 (en) | 2019-02-07 |
US20200103331A1 (en) | 2020-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lin et al. | Gold nanoparticle probes for the detection of mercury, lead and copper ions | |
Schmidt et al. | Quantitative characterization of gold nanoparticles by field-flow fractionation coupled online with light scattering detection and inductively coupled plasma mass spectrometry | |
Ulrich et al. | Critical aspects of sample handling for direct nanoparticle analysis and analytical challenges using asymmetric field flow fractionation in a multi-detector approach | |
Sapsford et al. | Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques | |
Khatun et al. | Elucidating diversity of exosomes: biophysical and molecular characterization methods | |
Polavarapu et al. | Optical sensing of biological, chemical and ionic species through aggregation of plasmonic nanoparticles | |
López-Sanz et al. | Analytical metrology for nanomaterials: Present achievements and future challenges | |
Wang et al. | Rational design and synthesis of SERS labels | |
Xu et al. | Chirality based sensor for bisphenol A detection | |
KR101986531B1 (en) | Anisotropic Nanostructures with Bimetallic Nanocluster and Conducting Polymer Compartment for Photonics-based Biosensing, process for producing the same, and use thereof | |
Zattoni et al. | Asymmetrical flow field-flow fractionation with multi-angle light scattering detection for the analysis of structured nanoparticles | |
US20230273107A1 (en) | Method, process, composition and kit for measuring concentration of molecules dissolved in the continuous phase of a colloid | |
Mudalige et al. | Simple functionalization strategies for enhancing nanoparticle separation and recovery with asymmetric flow field flow fractionation | |
US20070259437A1 (en) | Nanoparticulate Chemical Sensors Using SERS | |
Zhang et al. | SERS nanotags and their applications in biosensing and bioimaging | |
US8084275B2 (en) | Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface | |
WO2008016375A2 (en) | Modification of metal nanoparticles for improved analyte detection by surface enhanced raman spectroscopy (sers) | |
Ta et al. | Magnetic separation of elastin-like polypeptide receptors for enrichment of cellular and molecular targets | |
Kibar et al. | Newly designed silver coated-magnetic, monodisperse polymeric microbeads as SERS substrate for low-level detection of amoxicillin | |
Moreira-Alvarez et al. | Integrated analytical platforms for the comprehensive characterization of bioconjugated inorganic nanomaterials aiming at biological applications | |
Reschiglian et al. | Flow field-flow fractionation with multiangle light scattering detection for the analysis and characterization of functional nanoparticles | |
Cheng et al. | SERS nanoprobes for bio-application | |
Subramaniam et al. | Varying nanoparticle pseudostationary phase plug length during capillary electrophoresis | |
Otter et al. | Mechanically interlocked gold and silver nanoparticles using metallosupramolecular catenane chemistry | |
Contado et al. | Size sorting of citrate reduced gold nanoparticles by sedimentation field-flow fractionation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |